The Center will work closely with other human immunology centers at VUMC. The Center for Drug Safety will also work closely with the Immunogenomics and Single Cell Technologies Core. The extreme clinical phenotypes that have been enrolled into the Center’s IM-ADR studies have already provided the basis for a robust research and development pipeline associated with technologies developed within the Center for Translational Immunology and Infectious Diseases.